A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, that function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients across a broad range of disease areas and indications.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.7B | 3.7B | 2.2B | 1.8B | 1.0B | 844M |
| Net Income | 314M | 314M | -278M | -440M | -1.1B | -853M |
| EPS | $2.33 | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
| Free Cash Flow | 465M | 465M | -43M | 42M | -613M | -718M |
| ROIC | 118.7% | 113.7% | -25.5% | -55.0% | -131.7% | -67.5% |
| Gross Margin | 81.8% | 81.8% | 86.4% | 85.3% | 69.6% | 86.4% |
| Debt/Equity | 1.62 | 1.62 | 19.32 | -5.92 | -8.34 | 1.70 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 502M | 502M | -177M | -282M | -785M | -709M |
| Operating Margin | 13.5% | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| ROE | 39.8% | 73.3% | -414.6% | - | - | -145.0% |
| Shares Outstanding | 135M | 135M | 128M | 125M | 122M | 118M |
ALNYLAM PHARMACEUTICALS, INC. passes 3 of 9 quality checks, indicating weak fundamentals.
ALNYLAM PHARMACEUTICALS, INC. trades at 142.9x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Expensive relative to its historical range. The company's 5-year average gross margin is 81.9%.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a current P/E ratio of 142.9, compared to its historical median P/E of 15.0. The stock is currently considered Expensive based on its historical valuation range.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a 5-year average return on invested capital (ROIC) of -33.2%. This is below average and may indicate limited pricing power.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a market capitalization of $44.8B. It is classified as a large-cap stock.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) does not currently pay a regular dividend.
Based on historical P/E analysis, ALNYLAM PHARMACEUTICALS, INC. (ALNY) appears expensive. The current P/E of 142.9 is 853% above its historical median of 15.0.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported annual revenue of $3.7 billion in its most recent fiscal year, based on SEC EDGAR filings.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a net profit margin of 8.4%. This is a modest margin.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) generated $465 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a debt-to-equity ratio of 1.62. This indicates higher leverage, which may increase financial risk.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported earnings per share (EPS) of $2.33 in its most recent fiscal year.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a return on equity (ROE) of 73.3%. This indicates the company generates strong returns for shareholders.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a 5-year average gross margin of 81.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for ALNYLAM PHARMACEUTICALS, INC. (ALNY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ALNYLAM PHARMACEUTICALS, INC. (ALNY) has a book value per share of $5.86, based on its most recent annual SEC filing.